The Venture Codex Logo

The Venture Codex

Trium Ventures

3rd Floor, Rock Tower, The Rock Drive, Lekki Phase 1, Lagos, 100242, Nigeria

Overview

Trium Limited is a premier venture builder and venture capital firm dedicated to transforming Africa with technology, capital and expertise. We focus on early-stage investments, venture building, deal sourcing, investment portfolio management and venture advisory to identify, develop and scale innovative ventures across the continent. As a SEC-registered alternative investment firm, our mission is to lead Africa's digital transformation by investing in and building sustainable business models, accelerating growth, and delivering returns for our partners while driving meaningful change. Some of our key products include Incubation Management, Alternative Investment Management, Startup Investing and Venture Advisory.

Total investments
2
Lead investments
0
Investments · 12mo
0
Active investors
3

Sector focus

  • Venture Capital
Visit website

Investment portfolio

  • Artera

    Participated · Equity · Feb 2024

    ArteraAI develops multimodal artificial intelligence (MMAI) biomarker tests that combine digital biopsy-image analysis and patient clinical data to provide predictive and prognostic results. Its flagship ArteraAI Prostate Test is designed to predict whether a patient will benefit from a particular therapy and to determine prognosis for localized prostate cancer. The MMAI algorithm has been validated using many Phase 3 randomized trials. The test is clinically available through a CLIA-certified laboratory in Jacksonville, Florida. The company says it will use new funding to support international expansion and commercial growth of the company and its test. ArteraAI is led by CEO Andre Esteva and focuses on personalizing cancer therapy through AI-enabled diagnostics. Artera builds multimodal artificial intelligence tests that provide prognostic risk stratification and predict therapeutic benefit for cancer patients. Its flagship product, the ArteraAI Prostate Test, is described as the first test to predict therapy benefit in localized prostate cancer. The company launched publicly with $90 million in funding from a syndicate of institutional and angel investors to support U.S. and international distribution of the prostate test. Artera plans to use the investment to develop additional tests to support therapy personalization in other cancers. The ArteraAI Prostate Test is clinically available as a laboratory-developed test through a CLIA-certified laboratory in Jacksonville, Florida and can be ordered online. The company reported positive data at ASCO GU 2023 showing validation of its prognostic biomarker across six phase III randomized trials.

  • Sparkle

    Participated · Seed · Oct 2021

    Sparkle is a Nigerian neobank that combines personal banking, business banking and lifestyle services on a single platform. The app offers savings, bill payments, top-ups, transfers, bill splitting, spending breakdowns and features like transaction-by-beneficiary history, location confirmation and scheduled payments. In April Sparkle launched Sparkle Business to serve SMBs with inventory and invoice management, tax advice, payroll and employee management accessible with just a TIN and email. Since launching last year Sparkle has acquired over 40,000 individual customers and 2,000 businesses, and it operates under a microfinance bank license. The company has partnerships with Visa, Network International and PwC Nigeria. Sparkle has begun charging individual customers small account fees and plans to charge businesses for most features while keeping taxation services free. Future plans include building robotic process automation and hiring across engineering, finance, risk and marketing.

Team

  • Adebayo Adewolu

    Chief Executive Officer

  • OLATUNDE KING

    Head, Legal and Compliance

    LinkedIn
  • Oluwasanmi Owoso

    Head, Finance

    LinkedIn